NCT07275541 Platelet Aggregation in the Diagnosis of Acute Graft Rejection
| NCT ID | NCT07275541 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Martin |
| Condition | Platelet Aggregation |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2024-11-26 |
| Primary Completion | 2026-11-26 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 60 participants in total. It began in 2024-11-26 with a primary completion date of 2026-11-26.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study titled "Platelet Aggregation in the Diagnosis of Acute Graft Rejection" is a pilot observational study evaluating whether alterations in platelet function can serve as non-invasive markers of acute rejection in kidney transplant recipients. Platelet aggregation is assessed using optical aggregometry, flow-cytometric P-selectin (CD62-P) expression, and soluble P-selectin levels before kidney transplantation and at the time of protocol biopsies performed at 3 and 12 months after kidney transplantation. Patients with suspected graft dysfunction undergoing indication biopsy are also included. Platelet activation markers are correlated with histopathological findings, donor-specific antibodies, metabolic parameters, and clinical outcomes. The goal is to determine whether platelet activation profiles can identify acute cellular or antibody-mediated rejection and contribute to the development of a non-invasive diagnostic tool.
Eligibility Criteria
Inclusion Criteria: * adult patients (≥18 years) * primary kidney transplantation * living / deceased donor kidney transplantation * ability and consent to participate Exclusion Criteria: * non-adult patients * secondary / tertiary kidney transplantation * antiplatelet therapy * patients unable to provide informed consent
Contact & Investigator
Matej Vnucak, ass prof, MD, PhD.
STUDY CHAIR
University Hospital Martin and Jessenius Faculty of Medicine, Comenius University
Frequently Asked Questions
Who can join the NCT07275541 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Platelet Aggregation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07275541 currently recruiting?
Yes, NCT07275541 is actively recruiting participants. Contact the research team at tc@unm.sk for enrollment information.
Where is the NCT07275541 trial being conducted?
This trial is being conducted at Martin, Slovakia.
Who is sponsoring the NCT07275541 clinical trial?
NCT07275541 is sponsored by University Hospital, Martin. The principal investigator is Matej Vnucak, ass prof, MD, PhD. at University Hospital Martin and Jessenius Faculty of Medicine, Comenius University. The trial plans to enroll 60 participants.